青少年特发性脊柱侧凸后路融合内固定术后血清金属纳米颗粒水平升高
该单中心回顾性队列研究纳入336例青少年特发性脊柱侧凸(AIS)患者,比较手术植入物组与非手术对照组血清Ti、Co、Cr浓度。结果显示术后各时间点植入组金属离子均高于对照组,12个月达峰并持续升高至少4年;取出植入物后金属离子水平下降。金属离子浓度与植入物负荷及类型相关。
要点
- AIS后路融合术后血清Ti、Co、Cr升高,12个月达峰,持续至少4年。
- 取出植入物后金属离子水平下降,12个月时与对照组无差异。
- 金属离子浓度与棒长度、螺钉数量及Co-Cr-Mo植入物使用正相关。
核心结论
- AIS后路脊柱融合术后血清Ti、Co、Cr升高,提示植入物持续释放金属离子。
- 取出植入物可降低血清金属离子水平,证实植入物是金属纳米颗粒释放的主要来源。
- 金属离子浓度与植入物负荷(棒长度、螺钉数量)及植入物类型相关。
- 金属离子升高的临床重要性需进一步确认,目前不推荐常规检测或取出植入物。
研究设计与样本
- 单中心回顾性队列研究,2018年1月至2020年12月在城市三级转诊医院进行。
- 共纳入336例AIS患者,其中201例接受手术治疗,135例接受非手术治疗。
- 手术组最终分析96例仅植入组、46例翻修未取出组、15例取出组;对照组最终纳入105例。
- 采用电感耦合等离子体质谱法测定血清Ti、Co、Cr水平,多个术后时间点检测。
- 对取出植入物进行扫描电子显微镜联合能量色散X射线光谱分析。
主要发现
- 术后48个月,植入组血清Ti为1.1±0.3 μg/L,对照组为0.2±0.1 μg/L(均差0.9 μg/L,95%CI 0.8至1.0;p<0.001)。
- 术后48个月,植入组血清Co为0.3±0.2 μg/L,对照组为0.2±0.1 μg/L(均差0.1 μg/L,95%CI 0.1至0.2;p<0.001)。
- 术后48个月,植入组血清Cr为1.0±0.5 μg/L,对照组为0.1±0.1 μg/L(均差0.9 μg/L,95%CI 0.6至0.7;p<0.001)。
- 取出术后6个月,Ti下降1.8 μg/L(95%CI -2.1至-1.6;p<0.001),Co下降0.4 μg/L(95%CI -0.5至-0.3;p<0.001),Cr下降1.2 μg/L(95%CI -1.4至-1.0;p<0.001)。
- 取出术后12个月,取出组与对照组Ti、Co、Cr浓度均无差异(p值分别为0.38、0.62、0.45)。
关键数值与推荐
- 血清金属浓度与棒长度正相关(r=0.85至0.87,p<0.001),与螺钉数量正相关(r=0.87至0.88,p<0.001)。
- 血清金属浓度与棒直径正相关(β=0.54至0.58,p<0.001)。
- 血清Co浓度与使用Co-Cr-Mo植入物正相关(β=0.54,p<0.001),血清Cr浓度亦正相关(β=0.58,p<0.001)。
- SEM分析证实植入物表面腐蚀和纳米级缺陷,与金属释放一致。
临床怎么用
- 目前证据为初步结果,不推荐对AIS术后患者常规进行金属离子检测或影像学检查。
- 不推荐基于金属离子水平做出取出植入物的决策。
- 未来研究可尝试将离子水平与症状或影像学结果相关联。
局限性
- 单中心回顾性设计,可能存在选择偏倚。
- 部分患者因失访或合并其他部位金属植入物被排除。
- 金属离子升高的临床重要性尚未确认,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implantation of titanium alloys (Ti-6Al-4V) or cobalt-chromium-molybdenum alloys (Co-Cr-Mo) for long-segment spinal fixation is the standard surgical treatment for adolescent idiopathic scoliosis (AIS), but long-term presence of the implants in the body may lead to the release of metal nanoparticles. Unlike orthopaedic internal fixation surgeries, spinal implants generally remain in the human body for a lifetime. The release of metal nanoparticles remains a potential clinical issue, but currently there is a lack of strong data on the topic. This study aimed to fill this crucial knowledge gap by providing longitudinal evidence on the dynamics of metal ion release. This is the first step in determining safety characteristics and clinical thresholds. QUESTIONS/PURPOSES: (1) Are serum Ti, Co, and Cr concentrations in patients with AIS after implantation elevated compared with in patients without implantation over a 4-year period? (2) Does surgical removal of implants lead to a reduction in systemic metal nanoparticle load? (3) Is there a correlation between metal ion levels and implant burden? (4) Does implant type (Ti-6Al-4V versus Co-Cr-Mo) influence serum metal concentrations? METHODS: This was a single-center retrospective cohort study performed at an urban tertiary referral hospital from January 2018 to December 2020. A total of 336 patients with AIS were included, including 60% (201 of 336) who underwent surgical treatment and 40% (135 of 336) who received nonsurgical treatment. Among the 201 patients who underwent AIS operations, 6% (13 of 201) were excluded because of the presence of metal implants in other parts (ulna and radius [n = 5], around the elbow joint [n = 4], femoral shaft [n = 4]), and 15% (31 of 201) were excluded because they were lost to follow-up, resulting in incomplete clinical data. Forty-eight percent (96 of 201) of the patients only received spinal implant treatment without revision surgery (implant group), 23% (46 of 201) of the patients received spinal implant treatment and underwent revision surgery but did not have the implants removed (revision group), and 7% (15 of 201) of the patients received spinal implant treatment, underwent revision surgery, and had the implants removed (removal group). Among the 135 patients with AIS who did not undergo surgery, 6% (8 of 135) were excluded because of the presence of metal implants in other parts (ulna and radius [n = 3], around the elbow joint [n = 3], femoral shaft [n = 2]), and 16% (22 of 135) were excluded because they were lost to follow-up, resulting in incomplete clinical data. Seventy-eight percent (105 of 135) of the patients who did not undergo surgery who met the inclusion criteria were ultimately included in the control group. Since 2015, according to a standardized protocol, serum samples from patients undergoing surgery for AIS and from the nonsurgical control group have been collected. This is part of a broader and ongoing research project for patients with AIS. Between February and April 2025, we determined the metal ion concentrations in the collected blood samples. Serum Ti, Co, and Cr levels were measured via inductively coupled plasma mass spectrometry at multiple postoperative time points. The correlation between metal ion levels and rod length as well as the number of screws were evaluated using correlation analysis. Linear regression analysis was employed to assess the relationship between implant types (Ti-6Al-4V and Co-Cr-Mo), rod diameter, and serum metal concentrations. The extracted implants were subjected to scanning electron microscopy (SEM) combined with energy-dispersive x-ray spectroscopy analysis to examine the surface morphology and elemental composition of the implants. RESULTS: Serum concentrations of Ti, Co, and Cr were higher in patients with spinal implants than in nonsurgical controls at all postoperative time points. At 48 months, the mean ± SD serum Ti was 1.1 ± 0.3 μg/L in the implant group versus 0.2 ± 0.1 μg/L in controls (mean difference 0.9 μg/L [95% confidence interval (95% CI) 0.8 to 1.0]; p < 0.001), for Co it was 0.3 ± 0.2 μg/L versus 0.2 ± 0.1 μg/L (mean difference 0.1 μg/L [95% CI 0.1 to 0.2]; p < 0.001), and for Cr it was 1.0 ± 0.5 μg/L versus 0.1 ± 0.1 μg/L (mean difference 0.9 μg/L [95% CI 0.6 to 0.7]; p < 0.001). Metal levels peaked at 12 months postoperatively and remained elevated for 48 months. Implant removal was associated with a reduction in serum metal concentrations. At 6 months after removal, Ti levels decreased by 1.8 μg/L (95% CI -2.1 to -1.6; p < 0.001), Co levels by 0.4 μg/L (95% CI -0.5 to -0.3; p < 0.001), and Cr levels by 1.2 μg/L (95% CI -1.4 to -1.0; p < 0.001) compared with the removal group. At 12 months after removal surgery, there was no difference in Ti ion concentration between the removal group and the control group (0.2 ± 0.2 versus 0.2 ± 0.1, mean difference 0.0 [95% CI -0.2 to 0.1]; p = 0.38). Similarly, no difference was observed in Co ion concentration (0.2 ± 0.1 versus 0.2 ± 0.1, mean difference 0.0 [95% CI -0.1 to 0.1]; p = 0.62). Additionally, Cr ion concentration did not differ between groups (0.2 ± 0.1 versus 0.1 ± 0.1, mean difference 0.1 [95% CI -0.2 to 0.1]; p = 0.45). Serum metal concentrations correlated positively with implant load (rod length r = 0.85 to 0.87, number of screws r = 0.87 to 0.88; all p < 0.001) and rod diameter (β = 0.54 to 0.58; all p < 0.001).The serum Co concentration had a substantial positive correlation with the use of Co-Cr-Mo implants (β = 0.54; p < 0.001). Similarly, the serum Cr concentration had a substantial positive correlation with the use of Co-Cr-Mo implants (β = 0.58; p < 0.001). SEM analysis confirmed implant surface corrosion and nanoscale defects consistent with metal release. CONCLUSION: Serum levels of Ti, Co, and Cr increase after posterior spinal fusion in patients with AIS, reaching a peak at 12 months after operation, and remaining elevated for at least 4 years, which suggests continuous release of metal ions from the implants. Removal of the implants was associated with a reduction in serum metal ion levels, confirming that the implants are the main source of metal nanoparticle release. The concentration of metal ions is related to the burden of the implant (such as the length of the rod and the number of screws) and the type of implant. However, the clinical importance of elevated metal ions needs further confirmation. Our findings are preliminary and do not support routine metal ion tests or imaging examinations in patients with AIS treated surgically or recommendations regarding implant removal; however, future research may attempt to correlate ion levels with symptoms or imaging results in the study environment. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Wang Y, Li T, Xiang G, et al. Are Levels of Blood Metal Nanoparticles Elevated After Spinal Fusion and Implantation in Patients With Adolescent Idiopathic Scoliosis? Clin Orthop Relat Res. 2026. PMID: 42049197. doi:10.1097/CORR.0000000000003964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。